Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression.

Dr. Bhavna Rani, PhD
Dr. Bhavna Rani, PhD
Uppsala University
Post-Doctoral Research Fellow
Oncology, Cell/Molecular Biology, Hepatology, Neurology
Uppsala, Uppsala | Sweden

Cell Death Dis 2018 03 7;9(3):373. Epub 2018 Mar 7.

National Institute of Gastroenterology "S. de Bellis" Research Hospital, Castellana Grotte, Bari, Italy.

Cancer stem cells (CSCs) niche in the tumor microenvironment is responsible for cancer recurrence and therapy failure. To better understand its molecular and biological involvement in hepatocellular carcinoma (HCC) progression, one can design more effective therapies and tailored then to individual patients. While sorafenib is currently the only approved drug for first-line treatment of advanced stage HCC, its role in modulating the CSC niche is estimated to be small. By contrast, transforming growth factor (TGF)-β pathway seems to influence the CSC and thus may impact hallmarks of HCC, such as liver fibrosis, cirrhosis, and tumor progression. Therefore, blocking this pathway may offer an appealing and druggable target. In our study, we have used galunisertib (LY2157299), a selective ATP-mimetic inhibitor of TGF-β receptor I (TGFβI/ALK5) activation, currently under clinical investigation in HCC patients. Because the drug resistance is mainly mediated by CSCs, we tested the effects of galunisertib on stemness phenotype in HCC cells to determine whether TGF-β signaling modulates CSC niche and drug resistance. Galunisertib modulated the expression of stemness-related genes only in the invasive (HLE and HLF) HCC cells inducing a decreased expression of CD44 and THY1. Furthermore, galunisertib also reduced the stemness-related functions of invasive HCC cells decreasing the formation of colonies, liver spheroids and invasive growth ability. Interestingly, CD44 loss of function mimicked the galunisertib effects on HCC stemness-related functions. Galunisertib treatment also reduced the expression of stemness-related genes in ex vivo human HCC specimens. Our observations are the first evidence that galunisertib effectiveness overcomes stemness-derived aggressiveness via decreased expression CD44 and THY1.

Download full-text PDF

Source Listing
March 2018
70 Reads
5.014 Impact Factor

Publication Analysis

Top Keywords

hcc cells
decreased expression
cd44 thy1
expression cd44
expression stemness-related
csc niche
drug resistance
stemness-related functions
stemness-related genes
hepatocellular carcinoma
investigation hcc
hcc patients
patients drug
overcomes stemness-derived
currently clinical
receptor tgfβi/alk5
tgfβi/alk5 activation


(Supplied by CrossRef)
Article in Lancet
A Forner et al.
Lancet 2012
Article in Aliment. Pharmacol. Ther.
N Snowberger et al.
Aliment. Pharmacol. Ther. 2007
Article in Acta Pharmacol. Sin.
T Severi et al.
Acta Pharmacol. Sin. 2010
Article in Eur. J. Clin. Invest.
G Giannelli et al.
Eur. J. Clin. Invest. 2016
Article in Cell Death Dis.
Y Cao et al.
Cell Death Dis. 2017
Article in Nat. Rev. Gastroenterol. Hepatol.
T Tsuchida et al.
Nat. Rev. Gastroenterol. Hepatol. 2017
Article in Semin. Liver Dis.
T Roskams et al.
Semin. Liver Dis. 2010
Article in Gut
G Giannelli et al.
Gut 2014
Article in Cell Death Dis.
R Critelli et al.
Cell Death Dis. 2017
Article in J. Hepatol.
G Giannelli et al.
J. Hepatol. 2016
Article in Gastroenterology
D Sia et al.
Gastroenterology 2017

Similar Publications